Header Logo

Connection

Theodore Levin to Colorectal Neoplasms

Back to Details
This is a "connection" page, showing publications Theodore Levin has written about Colorectal Neoplasms.
Theodore Levin
Connection Strength
15.691
Colorectal Neoplasms
  1. Association between Improved Colorectal Screening and Racial Disparities. N Engl J Med. 2022 02 24; 386(8):796-798.
    View in: PubMed
    Score: 0.509
  2. Disparities in Preventable Mortality from Colorectal Cancer: Are They the Result of Structural Racism? Gastroenterology. 2021 03; 160(4):1022-1025.
    View in: PubMed
    Score: 0.470
  3. Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. Gastroenterology. 2020 11; 159(5):1695-1704.e1.
    View in: PubMed
    Score: 0.455
  4. What Is Organized Screening and What Is Its Value? Gastrointest Endosc Clin N Am. 2020 Jul; 30(3):393-411.
    View in: PubMed
    Score: 0.447
  5. Effects of Organized Colorectal Cancer Screening on Cancer Incidence and Mortality in a Large Community-Based Population. Gastroenterology. 2018 11; 155(5):1383-1391.e5.
    View in: PubMed
    Score: 0.396
  6. Performance of a quantitative fecal immunochemical test for detecting advanced colorectal neoplasia: a prospective cohort study. BMC Cancer. 2018 May 02; 18(1):509.
    View in: PubMed
    Score: 0.390
  7. Colorectal Cancer Screening: Money Isn't Everything . . . But It Helps! Gastroenterology. 2017 11; 153(5):1181-1183.
    View in: PubMed
    Score: 0.375
  8. Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test. JAMA. 2017 08 01; 318(5):483.
    View in: PubMed
    Score: 0.371
  9. Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA. 2017 Apr 25; 317(16):1631-1641.
    View in: PubMed
    Score: 0.364
  10. In simulation modelling, there are multiple ways to effectively screen for colorectal cancer. Evid Based Med. 2017 04; 22(2):59.
    View in: PubMed
    Score: 0.357
  11. Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue. Dig Dis Sci. 2017 03; 62(3):678-688.
    View in: PubMed
    Score: 0.356
  12. Fecal Immunochemical Test (FIT) for Colon Cancer Screening: Variable Performance with Ambient Temperature. J Am Board Fam Med. 2016 11 12; 29(6):672-681.
    View in: PubMed
    Score: 0.353
  13. Beyond Colonoscopy: The Role of Alternative Screening Tests for Colorectal Cancer in Your Practice. Am J Gastroenterol. 2017 01; 112(1):8-10.
    View in: PubMed
    Score: 0.352
  14. Colorectal-cancer screening--coming of age. N Engl J Med. 2013 Sep 19; 369(12):1164-6.
    View in: PubMed
    Score: 0.284
  15. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol. 2013 Sep; 11(9):1158-66.
    View in: PubMed
    Score: 0.274
  16. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012 Sep; 143(3):844-857.
    View in: PubMed
    Score: 0.261
  17. Automated phone and mail population outreach to promote colorectal cancer screening. Am J Manag Care. 2012 Jul; 18(7):370-8.
    View in: PubMed
    Score: 0.261
  18. The importance of choosing colorectal cancer screening tests: comment on "Adherence to colorectal cancer screening". Arch Intern Med. 2012 Apr 09; 172(7):582-3.
    View in: PubMed
    Score: 0.256
  19. Editorial: taking FIT to the people: out of the office and into the mail. Am J Gastroenterol. 2012 Jan; 107(1):108-10.
    View in: PubMed
    Score: 0.252
  20. Optimizing colorectal cancer screening by getting FIT right. Gastroenterology. 2011 Nov; 141(5):1551-5.
    View in: PubMed
    Score: 0.247
  21. Organized colorectal cancer screening in integrated health care systems. Epidemiol Rev. 2011; 33:101-10.
    View in: PubMed
    Score: 0.243
  22. Editorial: It's time to make organized colorectal cancer screening convenient and easy for patients. Am J Gastroenterol. 2009 Apr; 104(4):939-41.
    View in: PubMed
    Score: 0.207
  23. Colonoscopic screening of women for colorectal neoplasia. N Engl J Med. 2005 Aug 25; 353(8):844-6; author reply 844-6.
    View in: PubMed
    Score: 0.162
  24. Quality in the technical performance of screening flexible sigmoidoscopy: recommendations of an international multi-society task group. Gut. 2005 Jun; 54(6):807-13.
    View in: PubMed
    Score: 0.159
  25. Incomplete screening flexible sigmoidoscopy associated with female sex, age, and increased risk of colorectal cancer. Gut. 2005 Sep; 54(9):1273-8.
    View in: PubMed
    Score: 0.159
  26. Colonoscopy capacity: Can we build it? Will they come? Gastroenterology. 2004 Dec; 127(6):1841-4.
    View in: PubMed
    Score: 0.154
  27. Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death. JAMA Netw Open. 2024 Jul 01; 7(7):e2423671.
    View in: PubMed
    Score: 0.150
  28. Surveillance Colonoscopy Findings in Older Adults With a History of Colorectal Adenomas. JAMA Netw Open. 2024 Apr 01; 7(4):e244611.
    View in: PubMed
    Score: 0.147
  29. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults. Ann Intern Med. 2024 Apr; 177(4):542-543.
    View in: PubMed
    Score: 0.147
  30. Colorectal Cancer Screening After Sequential Outreach Components in a Demographically Diverse Cohort. JAMA Netw Open. 2024 Apr 01; 7(4):e245295.
    View in: PubMed
    Score: 0.147
  31. Factors associated with colorectal cancer screening in a population-based study: the impact of gender, health care source, and time. Prev Med. 2004 Mar; 38(3):276-83.
    View in: PubMed
    Score: 0.146
  32. Unsatisfactory Fecal Immunochemical Tests for Colorectal Cancer Screening: Prevalence, Reasons, and Subsequent Testing. Cancer Epidemiol Biomarkers Prev. 2024 Feb 06; 33(2):215-223.
    View in: PubMed
    Score: 0.146
  33. What does sigmoidoscopy really miss? Am J Gastroenterol. 2003 Oct; 98(10):2326-7.
    View in: PubMed
    Score: 0.142
  34. Does Screening Colonoscopy Have a Future in the United States? Clin Gastroenterol Hepatol. 2023 11; 21(12):3005-3010.
    View in: PubMed
    Score: 0.140
  35. Re: Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. J Natl Cancer Inst. 2003 Jun 04; 95(11):830-1; author reply 831.
    View in: PubMed
    Score: 0.139
  36. Does family history still matter in the era of screening colonoscopy? Clin Gastroenterol Hepatol. 2003 Mar; 1(2):69-70.
    View in: PubMed
    Score: 0.136
  37. Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning Ten Years after a Negative Colonoscopy, among Screen-Eligible Adults 76 to 85 Years Old. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):37-45.
    View in: PubMed
    Score: 0.135
  38. Impact and Recovery from COVID-19-Related Disruptions in Colorectal Cancer Screening and Care in the US: A Scenario Analysis. Cancer Epidemiol Biomarkers Prev. 2023 01 09; 32(1):22-29.
    View in: PubMed
    Score: 0.135
  39. Complications of screening flexible sigmoidoscopy. Gastroenterology. 2002 Dec; 123(6):1786-92.
    View in: PubMed
    Score: 0.134
  40. Flexible sigmoidoscopy for colorectal cancer screening: valid approach or short-sighted? Gastroenterol Clin North Am. 2002 Dec; 31(4):1015-29, vii.
    View in: PubMed
    Score: 0.134
  41. Could screening for colorectal cancer be harmful? Am J Gastroenterol. 2002 Jan; 97(1):198.
    View in: PubMed
    Score: 0.126
  42. Flexible sigmoidoscopy: an important screening option for average-risk individuals. Gastrointest Endosc Clin N Am. 2002 Jan; 12(1):23-40, vi.
    View in: PubMed
    Score: 0.126
  43. Heterogeneity in colorectal cancer incidence among people recommended 3-yearly surveillance post-polypectomy: a validation study. Endoscopy. 2021 Apr; 53(4):402-410.
    View in: PubMed
    Score: 0.114
  44. Mailed fecal immunochemical test outreach for colorectal cancer screening: Summary of a Centers for Disease Control and Prevention-sponsored Summit. CA Cancer J Clin. 2020 07; 70(4):283-298.
    View in: PubMed
    Score: 0.113
  45. The effect of using fecal testing after a negative sigmoidoscopy on the risk of death from colorectal cancer. J Med Screen. 2021 06; 28(2):140-147.
    View in: PubMed
    Score: 0.113
  46. Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population. Clin Gastroenterol Hepatol. 2020 11; 18(12):2734-2741.e6.
    View in: PubMed
    Score: 0.112
  47. Increased Risk of Colorectal Cancer in Individuals With a History of Serrated Polyps. Gastroenterology. 2020 08; 159(2):502-511.e2.
    View in: PubMed
    Score: 0.112
  48. Long-term Risk of Colorectal Cancer and Related Death After Adenoma Removal in a Large, Community-based Population. Gastroenterology. 2020 03; 158(4):884-894.e5.
    View in: PubMed
    Score: 0.108
  49. Influence of Varying Quantitative Fecal Immunochemical Test Positivity Thresholds on Colorectal Cancer Detection. Ann Intern Med. 2019 05 21; 170(10):736-737.
    View in: PubMed
    Score: 0.105
  50. Modifiable Failures in the Colorectal Cancer Screening Process and Their Association With Risk of Death. Gastroenterology. 2019 01; 156(1):63-74.e6.
    View in: PubMed
    Score: 0.100
  51. Index colonoscopy-related risk factors for postcolonoscopy colorectal cancers. Gastrointest Endosc. 2019 01; 89(1):168-176.e3.
    View in: PubMed
    Score: 0.100
  52. A Comparison of Fecal Immunochemical and High-Sensitivity Guaiac Tests for Colorectal Cancer Screening. Am J Gastroenterol. 2017 Nov; 112(11):1728-1735.
    View in: PubMed
    Score: 0.094
  53. Interventions to Improve Follow-up of Positive Results on Fecal Blood Tests: A Systematic Review. Ann Intern Med. 2017 Oct 17; 167(8):565-575.
    View in: PubMed
    Score: 0.094
  54. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017 07; 153(1):307-323.
    View in: PubMed
    Score: 0.092
  55. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 Jul; 112(7):1016-1030.
    View in: PubMed
    Score: 0.092
  56. Colorectal cancer screening: Recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2017 07; 86(1):18-33.
    View in: PubMed
    Score: 0.092
  57. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-society Task Force on Colorectal Cancer. J Pediatr Gastroenterol Nutr. 2017 05; 64(5):836-843.
    View in: PubMed
    Score: 0.091
  58. Colorectal Cancer Screening Initiation After Age 50 Years in an Organized Program. Am J Prev Med. 2017 Sep; 53(3):335-344.
    View in: PubMed
    Score: 0.091
  59. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 05; 112(5):682-690.
    View in: PubMed
    Score: 0.090
  60. Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc. 2017 05; 85(5):873-882.
    View in: PubMed
    Score: 0.090
  61. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017 05; 152(6):1605-1614.
    View in: PubMed
    Score: 0.090
  62. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017 04; 152(5):1217-1237.e3.
    View in: PubMed
    Score: 0.088
  63. Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017 01; 112(1):37-53.
    View in: PubMed
    Score: 0.088
  64. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on colorectal cancer. Gastrointest Endosc. 2017 Jan; 85(1):2-21.e3.
    View in: PubMed
    Score: 0.088
  65. Endoscopist fatigue estimates and colonoscopic adenoma detection in a large community-based setting. Gastrointest Endosc. 2017 Mar; 85(3):601-610.e2.
    View in: PubMed
    Score: 0.087
  66. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System. J Gen Intern Med. 2016 11; 31(11):1323-1330.
    View in: PubMed
    Score: 0.086
  67. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Clin Gastroenterol Hepatol. 2016 10; 14(10):1445-1451.e8.
    View in: PubMed
    Score: 0.085
  68. Colorectal cancer screening: 80% by 2018. Colonoscopists simply cannot do it alone. Gastrointest Endosc. 2016 Mar; 83(3):552-4.
    View in: PubMed
    Score: 0.084
  69. Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2016 Mar; 111(3):337-46; quiz 347.
    View in: PubMed
    Score: 0.084
  70. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar; 150(3):758-768.e11.
    View in: PubMed
    Score: 0.084
  71. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016 Apr 05; 164(7):456-63.
    View in: PubMed
    Score: 0.083
  72. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US multi-society task force on colorectal cancer. Gastrointest Endosc. 2016 Mar; 83(3):489-98.e10.
    View in: PubMed
    Score: 0.083
  73. Factors influencing variation in physician adenoma detection rates: a theory-based approach for performance improvement. Gastrointest Endosc. 2016 Mar; 83(3):617-26.e2.
    View in: PubMed
    Score: 0.081
  74. Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. JAMA. 2015 Jun 16; 313(23):2349-58.
    View in: PubMed
    Score: 0.080
  75. Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. BMC Cancer. 2015 Mar 14; 15:123.
    View in: PubMed
    Score: 0.079
  76. Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. Cancer. 2015 Jul 01; 121(13):2281-5.
    View in: PubMed
    Score: 0.079
  77. Ten-year incidence of colorectal cancer following a negative screening sigmoidoscopy: an update from the Colorectal Cancer Prevention (CoCaP) programme. Gut. 2016 Feb; 65(2):271-7.
    View in: PubMed
    Score: 0.077
  78. Colorectal cancer deaths attributable to nonuse of screening in the United States. Ann Epidemiol. 2015 Mar; 25(3):208-213.e1.
    View in: PubMed
    Score: 0.077
  79. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US multi-society task force on colorectal cancer. Gastroenterology. 2014 Oct; 147(4):903-24.
    View in: PubMed
    Score: 0.076
  80. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 Oct; 109(10):1528-45.
    View in: PubMed
    Score: 0.076
  81. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 06 26; 370(26):2541.
    View in: PubMed
    Score: 0.075
  82. The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium. Cancer Epidemiol Biomarkers Prev. 2014 Jul; 23(7):1147-58.
    View in: PubMed
    Score: 0.075
  83. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014 Apr 03; 370(14):1298-306.
    View in: PubMed
    Score: 0.074
  84. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014 Apr 03; 370(14):1287-97.
    View in: PubMed
    Score: 0.073
  85. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014 Feb 04; 160(3):171.
    View in: PubMed
    Score: 0.073
  86. Effectiveness and reach of the FLU-FIT program in an integrated health care system: a multisite randomized trial. Am J Public Health. 2013 Jun; 103(6):1128-33.
    View in: PubMed
    Score: 0.069
  87. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013 Mar 05; 158(5 Pt 1):312-20.
    View in: PubMed
    Score: 0.068
  88. The road ahead: what if gastroenterologists were accountable for preventing colorectal cancer? Clin Gastroenterol Hepatol. 2013 Mar; 11(3):204-7.
    View in: PubMed
    Score: 0.068
  89. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol. 2013 Feb; 11(2):172-80.
    View in: PubMed
    Score: 0.066
  90. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012 Aug; 143(2):382-9.
    View in: PubMed
    Score: 0.065
  91. The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc. 2011 Mar; 73(3):419-22.
    View in: PubMed
    Score: 0.059
  92. Lack of association between insulin sensitivity and colorectal adenoma risk. Nutr Cancer. 2011; 63(1):6-11.
    View in: PubMed
    Score: 0.059
  93. Serial glycosylated hemoglobin levels and risk of colorectal neoplasia among patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2010 Dec; 19(12):3027-36.
    View in: PubMed
    Score: 0.058
  94. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008 Oct 07; 149(7):441-50, W81.
    View in: PubMed
    Score: 0.050
  95. Implications of new colorectal cancer screening technologies for primary care practice. Med Care. 2008 Sep; 46(9 Suppl 1):S138-46.
    View in: PubMed
    Score: 0.050
  96. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008 May-Jun; 58(3):130-60.
    View in: PubMed
    Score: 0.048
  97. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008 May; 134(5):1570-95.
    View in: PubMed
    Score: 0.048
  98. Medical therapy for diabetes is associated with increased use of lower endoscopy. Pharmacoepidemiol Drug Saf. 2007 Nov; 16(11):1195-202.
    View in: PubMed
    Score: 0.047
  99. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007 Oct 03; 99(19):1462-70.
    View in: PubMed
    Score: 0.047
  100. Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc. 2007 May; 65(6):757-66.
    View in: PubMed
    Score: 0.046
  101. Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev. 2007 Mar; 16(3):526-31.
    View in: PubMed
    Score: 0.045
  102. Improved marker combination for detection of de novo genetic variation and aberrant DNA in colorectal neoplasia. Clin Chem. 2006 Dec; 52(12):2299-302.
    View in: PubMed
    Score: 0.044
  103. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2006 May; 130(6):1865-71.
    View in: PubMed
    Score: 0.042
  104. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology. 2006 May; 130(6):1872-85.
    View in: PubMed
    Score: 0.042
  105. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006 May-Jun; 56(3):143-59; quiz 184-5.
    View in: PubMed
    Score: 0.042
  106. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin. 2006 May-Jun; 56(3):160-7; quiz 185-6.
    View in: PubMed
    Score: 0.042
  107. Reducing unnecessary surveillance colonoscopies: a mandate for endoscopists. Gastrointest Endosc. 2006 Jan; 63(1):104-6.
    View in: PubMed
    Score: 0.042
  108. CYP1A1, cigarette smoking, and colon and rectal cancer. Am J Epidemiol. 2004 Nov 01; 160(9):842-52.
    View in: PubMed
    Score: 0.038
  109. The incidence of colorectal cancer following a negative screening sigmoidoscopy: implications for screening interval. Gastroenterology. 2004 Sep; 127(3):714-22.
    View in: PubMed
    Score: 0.038
  110. Quality indicators for colonoscopy. Gastrointest Endosc. 2024 Sep; 100(3):352-381.
    View in: PubMed
    Score: 0.038
  111. The evolution to stool DNA testing for colorectal cancer. Aliment Pharmacol Ther. 2004 Jun 15; 19(12):1225-33.
    View in: PubMed
    Score: 0.037
  112. Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004 Apr; 13(4):538-45.
    View in: PubMed
    Score: 0.037
  113. Family history and colorectal cancer: predictors of risk. Cancer Causes Control. 2003 Nov; 14(9):879-87.
    View in: PubMed
    Score: 0.036
  114. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology. 2003 Feb; 124(2):544-60.
    View in: PubMed
    Score: 0.034
  115. Hereditary nonpolyposis colorectal cancer in young colorectal cancer patients: high-risk clinic versus population-based registry. Gastroenterology. 2002 Apr; 122(4):940-7.
    View in: PubMed
    Score: 0.032
  116. [Search for microsatellite instability in colorectal cancer: an effective way to detect HNPCC?]. Gastroenterol Clin Biol. 2001 Oct; 25(10):929-31.
    View in: PubMed
    Score: 0.031
  117. Shifts in the Fecal Microbiota Associated with Adenomatous Polyps. Cancer Epidemiol Biomarkers Prev. 2017 01; 26(1):85-94.
    View in: PubMed
    Score: 0.022
  118. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. multi-society task force on colorectal cancer. Gastrointest Endosc. 2014 Oct; 80(4):543-562.
    View in: PubMed
    Score: 0.019
  119. Associations between apoE genotype and colon and rectal cancer. Carcinogenesis. 2005 Aug; 26(8):1422-9.
    View in: PubMed
    Score: 0.010

© 2024 Kaiser Permanente